Login to Your Account



DDW Roundup


Tuesday, May 10, 2011
ImmusanT Inc., of Cambridge, Mass., presented Phase I data showing that Nexvax2 was well tolerated and induced a T-cell response confirming bioactivity in HLA-DQ2 genotype celiac disease patients. Nexvax2 is a therapeutic vaccine that combines three peptides that elicit an immune response in patients with the immune recognition gene HLA-DQ2. A Phase IIa trial is expected to begin within a year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription